Table 4.

Chronic oral once-daily administration of AZD2171 inhibits established human tumor xenograft growth

Tumor xenograftTumor originDose (mg/kg/d)Tumor age at treatment onset (d)No. doses% Inhibition of tumor volumeSignificance (t test, one-tailed)
SW620Colon6.052894<0.001
3.052873<0.001
1.552843<0.001
0.7552837<0.01
Calu-6Lung6.0102891<0.001
3.0102869<0.001
1.5102849<0.01
0.75102826NS
PC-3Prostate6.0142898<0.001
3.0142884<0.001
1.5142839<0.01
0.75142818NS
MDA-MB-231Breast6.01424>100<0.001
3.0142499<0.001
1.5142475<0.001
0.75142465<0.001
SKOV-3Ovary6.01828>100<0.001
3.01828>100<0.001
1.5182881<0.01
0.75182852<0.05
  • NOTE: Nude mice bearing established human tumor xenografts (0.1-0.5 cm3 volume) were treated orally, once daily with AZD2171 (0.75-6 mg/kg/d) or vehicle [a 1% (w/v) solution of polyoxyethylene ( 20) sorbitan mono-oleate in deionized water]. Percentage tumor growth inhibition was calculated as the difference between the mean change in control and AZD2171-treated tumor volumes over the period of treatment. Statistical significance was examined on log-transformed data using a one-tailed t test (NS, P > 0.05). Mean control tumor volumes at the start of treatment were 0.2 cm3, with the exception of SKOV-3 tumors that were 0.3 cm3. Control tumor volumes at the end of vehicle treatment were 1.5 ± 0.1 cm3 (SW620), 1.1 ± 0.1 cm3 (Calu-6) 0.7 ± 0.1 cm3 (PC-3), 1.8 ± 0.2 cm3 (MDA-MB-231), and 0.9 ± 0.1 cm3 (SKOV-3).

    Abbreviation: NS, not significant.